Physician profile
Amit Chohan
NPI 1962016998
$5,312.20
in general payments reported to CMS, 2019-2025
20 companies · $847 in 2025
The $847 reported for 2025 was more than what 88% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $193 · 2022: $1,746 · 2023: $1,333 · 2024: $1,193 · 2025: $847.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,361 · Education: $12.19.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,360.82 |
| Education | $12.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $1,192.78 | 2022-2023 | |
| Sun Pharmaceutical Industries INC. | $975.78 | 2022-2025 | Cequa |
| Alcon Vision LLC | $601.32 | 2022-2025 | Dailies Total1, Precision 1, Total30 |
| Abbvie INC. | $388.55 | 2023-2025 | Vuity, Durysta |
| Tarsus Pharmaceuticals, INC. | $311.73 | 2024-2025 | Xdemvy |
| Novartis Pharmaceuticals Corporation | $246.33 | 2023 | |
| Amgen INC. | $236.20 | 2024-2025 | Tepezza |
| Coopervision INC. | $173.16 | 2021-2024 | Myday Contact Lens |
| Dompe US, INC. | $151.44 | 2024-2025 | Oxervate |
| Bausch & Lomb Americas INC. | $148.93 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Oyster Point Pharma, INC. | $134.55 | 2022-2025 | Tyrvaya, Ryzumvi |
| Horizon Therapeutics Plc | $126.60 | 2023 | Tepezza |
| Kala Pharmaceuticals, INC. | $125.00 | 2022 | |
| Quidel Corporation | $123.04 | 2022 | |
| Johnson & Johnson Vision Care, INC. | $120.26 | 2021-2024 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harrow Eye, LLC | $110.10 | 2024-2025 | Vevye |
| Thea Pharma INC. | $63.11 | 2023-2025 | Iyuzeh |
| Rxsight INC | $51.82 | 2024 | Rxsight Injector Handpiece, Light Adjustable Lens (Lal), Rxsight Injector Cartridge |
| Glaxosmithkline, LLC. | $18.72 | 2022 | |
| Eyevance Pharmaceuticals LLC | $12.78 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amit Chohan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.